FR2962436B1 - Derives de xanthedediones pour le traitement des troubles de la pigmentation et du vieillissement cutane - Google Patents

Derives de xanthedediones pour le traitement des troubles de la pigmentation et du vieillissement cutane

Info

Publication number
FR2962436B1
FR2962436B1 FR1055595A FR1055595A FR2962436B1 FR 2962436 B1 FR2962436 B1 FR 2962436B1 FR 1055595 A FR1055595 A FR 1055595A FR 1055595 A FR1055595 A FR 1055595A FR 2962436 B1 FR2962436 B1 FR 2962436B1
Authority
FR
France
Prior art keywords
xanthedediones
pigmentation
derivatives
treatment
skin aging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1055595A
Other languages
English (en)
Other versions
FR2962436A1 (fr
Inventor
Stephane Poigny
Francoise Belaubre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Dermo Cosmetique SA
Original Assignee
Pierre Fabre Dermo Cosmetique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1055595A priority Critical patent/FR2962436B1/fr
Application filed by Pierre Fabre Dermo Cosmetique SA filed Critical Pierre Fabre Dermo Cosmetique SA
Priority to CA2804334A priority patent/CA2804334A1/fr
Priority to RU2013103030/04A priority patent/RU2598374C2/ru
Priority to KR1020137003123A priority patent/KR20130043181A/ko
Priority to NZ605750A priority patent/NZ605750A/en
Priority to JP2013517403A priority patent/JP5829272B2/ja
Priority to US13/808,456 priority patent/US8906416B2/en
Priority to AU2011275686A priority patent/AU2011275686B2/en
Priority to SG2013000872A priority patent/SG186941A1/en
Priority to TW100124230A priority patent/TWI538693B/zh
Priority to CN201180034125.0A priority patent/CN102985415B/zh
Priority to MX2013000077A priority patent/MX2013000077A/es
Priority to ARP110102461A priority patent/AR082141A1/es
Priority to EP11730320.6A priority patent/EP2590959A1/fr
Priority to PCT/EP2011/061637 priority patent/WO2012004390A1/fr
Priority to MA35578A priority patent/MA34390B1/fr
Priority to BR112013000431A priority patent/BR112013000431A2/pt
Publication of FR2962436A1 publication Critical patent/FR2962436A1/fr
Publication of FR2962436B1 publication Critical patent/FR2962436B1/fr
Application granted granted Critical
Priority to IL224123A priority patent/IL224123A/en
Priority to ZA2013/00413A priority patent/ZA201300413B/en
Priority to HK13105388.4A priority patent/HK1178521A1/xx
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/08—Preparations for bleaching the hair
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
FR1055595A 2010-07-09 2010-07-09 Derives de xanthedediones pour le traitement des troubles de la pigmentation et du vieillissement cutane Expired - Fee Related FR2962436B1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FR1055595A FR2962436B1 (fr) 2010-07-09 2010-07-09 Derives de xanthedediones pour le traitement des troubles de la pigmentation et du vieillissement cutane
ARP110102461A AR082141A1 (es) 2010-07-09 2011-07-08 Derivados xantenodiona para el tratamiento de trastornos de pigmentacion y de envejecimiento de la piel
KR1020137003123A KR20130043181A (ko) 2010-07-09 2011-07-08 색소침착 및 피부노화 질환 치료용 잔텐디온 유도체
NZ605750A NZ605750A (en) 2010-07-09 2011-07-08 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders
JP2013517403A JP5829272B2 (ja) 2010-07-09 2011-07-08 色素沈着および皮膚老化障害の治療のためのキサンテンジオン誘導体
US13/808,456 US8906416B2 (en) 2010-07-09 2011-07-08 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders
AU2011275686A AU2011275686B2 (en) 2010-07-09 2011-07-08 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders
SG2013000872A SG186941A1 (en) 2010-07-09 2011-07-08 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders
TW100124230A TWI538693B (zh) 2010-07-09 2011-07-08 用於治療色素沉著與皮膚老化病症之二苯并哌喃二酮衍生物
CN201180034125.0A CN102985415B (zh) 2010-07-09 2011-07-08 用于治疗色素沉着和皮肤衰老疾病的呫吨二酮衍生物
CA2804334A CA2804334A1 (fr) 2010-07-09 2011-07-08 Derives de xanthenedione pour le traitement de troubles de pigmentation et de vieillissement de la peau
MX2013000077A MX2013000077A (es) 2010-07-09 2011-07-08 Derivados de xantendiona para el tratamiento de los desordenes de pigmentacion y envejecimiento de la piel.
MA35578A MA34390B1 (fr) 2010-07-09 2011-07-08 Dérivés de xanthènedione pour le traitement de troubles de pigmentation et de vieillissement de la peau
PCT/EP2011/061637 WO2012004390A1 (fr) 2010-07-09 2011-07-08 Dérivés de xanthènedione pour le traitement de troubles de pigmentation et de vieillissement de la peau
EP11730320.6A EP2590959A1 (fr) 2010-07-09 2011-07-08 Dérivés de xanthènedione pour le traitement de troubles de pigmentation et de vieillissement de la peau
BR112013000431A BR112013000431A2 (pt) 2010-07-09 2011-07-08 derivados de xantenodiona para o tratamento de distúrbios de pigmentação e envelhecimento de pele
RU2013103030/04A RU2598374C2 (ru) 2010-07-09 2011-07-08 Производные ксантендиона для лечения пигментации и старения кожи
IL224123A IL224123A (en) 2010-07-09 2013-01-06 Xanthindion derivatives for the treatment of pigmentation and skin aging disorders
ZA2013/00413A ZA201300413B (en) 2010-07-09 2013-01-16 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders
HK13105388.4A HK1178521A1 (en) 2010-07-09 2013-05-06 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1055595A FR2962436B1 (fr) 2010-07-09 2010-07-09 Derives de xanthedediones pour le traitement des troubles de la pigmentation et du vieillissement cutane

Publications (2)

Publication Number Publication Date
FR2962436A1 FR2962436A1 (fr) 2012-01-13
FR2962436B1 true FR2962436B1 (fr) 2012-12-14

Family

ID=43759812

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1055595A Expired - Fee Related FR2962436B1 (fr) 2010-07-09 2010-07-09 Derives de xanthedediones pour le traitement des troubles de la pigmentation et du vieillissement cutane

Country Status (20)

Country Link
US (1) US8906416B2 (fr)
EP (1) EP2590959A1 (fr)
JP (1) JP5829272B2 (fr)
KR (1) KR20130043181A (fr)
CN (1) CN102985415B (fr)
AR (1) AR082141A1 (fr)
AU (1) AU2011275686B2 (fr)
BR (1) BR112013000431A2 (fr)
CA (1) CA2804334A1 (fr)
FR (1) FR2962436B1 (fr)
HK (1) HK1178521A1 (fr)
IL (1) IL224123A (fr)
MA (1) MA34390B1 (fr)
MX (1) MX2013000077A (fr)
NZ (1) NZ605750A (fr)
RU (1) RU2598374C2 (fr)
SG (1) SG186941A1 (fr)
TW (1) TWI538693B (fr)
WO (1) WO2012004390A1 (fr)
ZA (1) ZA201300413B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142127A1 (fr) * 2013-03-12 2014-09-18 第一三共株式会社 Dérivé de phénylxanthène

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU895985A1 (ru) * 1980-03-27 1982-01-07 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср 9-Ароил-3,3,6,6-тетраметил-1,2,3,4,5,6,7,8-октагидроксантен-1,8-дионы в качестве промежуточных продуктов дл синтеза соединений,обладающих антиоксидантной активностью
JP3498857B2 (ja) * 1994-01-28 2004-02-23 株式会社ノエビア 皮膚外用剤
GB9707695D0 (en) * 1996-08-07 1997-06-04 Hoffmann La Roche Tricyclic dione derivatives
US7390668B2 (en) * 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
FR2756183B1 (fr) * 1996-11-25 1999-08-27 Fabre Pierre Dermo Cosmetique Association d'huile et de peptides d'argan utile pour le traitement des troubles lies au vieillissement cutane
EP2020242B1 (fr) * 1999-08-13 2011-10-19 Provectus Pharmatech, Inc. Médicaments topiques améliorés et procédés de traitement photodynamique de maladies
EP1213025A1 (fr) * 2000-12-06 2002-06-12 Laboratoires Serobiologiques(Societe Anonyme) Composition cosmétique et/ou dermopharmaceutique conténant un extrait obtenu à partir de feuilles d'Argania spinosa
GB0215534D0 (en) * 2002-07-04 2002-08-14 Ecole Polytech Selective photochemotherapy using oligonucleotide targeting agents
WO2006055688A1 (fr) * 2004-11-16 2006-05-26 Renaissance Herbs, Inc. Compositions pharmaceutiques et therapeutiques derivees de garcinia mangostana l.

Also Published As

Publication number Publication date
CN102985415B (zh) 2015-07-01
EP2590959A1 (fr) 2013-05-15
CA2804334A1 (fr) 2012-01-12
US20130108568A1 (en) 2013-05-02
TW201206488A (en) 2012-02-16
JP2013530203A (ja) 2013-07-25
IL224123A (en) 2016-06-30
TWI538693B (zh) 2016-06-21
JP5829272B2 (ja) 2015-12-09
AU2011275686B2 (en) 2014-11-27
KR20130043181A (ko) 2013-04-29
AR082141A1 (es) 2012-11-14
RU2598374C2 (ru) 2016-09-27
HK1178521A1 (en) 2013-09-13
RU2013103030A (ru) 2014-08-20
SG186941A1 (en) 2013-02-28
AU2011275686A1 (en) 2013-01-31
US8906416B2 (en) 2014-12-09
CN102985415A (zh) 2013-03-20
MA34390B1 (fr) 2013-07-03
FR2962436A1 (fr) 2012-01-13
MX2013000077A (es) 2013-03-18
ZA201300413B (en) 2013-09-25
WO2012004390A1 (fr) 2012-01-12
NZ605750A (en) 2015-12-24
BR112013000431A2 (pt) 2016-05-17

Similar Documents

Publication Publication Date Title
IL259547B (en) Isolated protein and preparations containing it for use in the treatment of disorders caused by il-1
HK1213192A1 (zh) 用於在人類受試者中治療眼部疾病的方法和裝置
PL2704704T3 (pl) Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry
EP2621499A4 (fr) Méthodes de traitement de maladies allergiques
IL225239A0 (en) Compounds for the treatment of acne and related diseases
HK1198909A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
IL223286A0 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
EP2723902A4 (fr) Traitement et diagnostic de troubles et d'états pathologiques épigénétiques
EP2515926A4 (fr) Compositions et méthodes pour le traitement de maladies ophtalmiques liées à une angiogenèse
PL2701645T3 (pl) Urządzenie do leczenia i/lub zapobiegania chorobom rogówki
IL239629A0 (en) History of benzylideneguanidine and therapeutic use for the treatment of diseases resulting from misfolding of proteins
HK1204573A1 (en) Treatment of inflammatory skin disorders
FR2992173B1 (fr) Procece cosmetique d'eclaircissement de la peau et/ou des levres
EP2709632A4 (fr) Compositions et procédés pour le traitement de maladies de la peau
EP2681209A4 (fr) Composés et méthodes de traitement de la douleur et d'autres troubles
EP2838521A4 (fr) Formulations et procédés pour le traitement de plaies et d'affections cutanées inflammatoires
EP2723325A4 (fr) Nouvelles formulations et méthodes de traitement de troubles ou de maladies dermatologiques
GB201114289D0 (en) Flurbiprofen and related compounds for the treatment of skin diseases
HK1158954A1 (en) 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases
FR2992315B1 (fr) Derives utiles dans le traitement de maladies du systeme nerveux central
FR2962436B1 (fr) Derives de xanthedediones pour le traitement des troubles de la pigmentation et du vieillissement cutane
ZA201408045B (en) Compositions and methods for the treatment of inflammation and lipid disorders
GB0814043D0 (en) The treatment of skin disorders
FR2963238B1 (fr) Derives de 15-desoxyspergualine pour le traitement et/ou la prevention des maladies inflammatoires oculaires
AU2012902874A0 (en) Treatment of inflammatory skin disorders

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 7

ST Notification of lapse

Effective date: 20180330